Finzati - Logo
LBRX logo

LB Pharmaceuticals Inc Common Stock

LBRX • Biotechnology
$49.34
▲ +1.82 (+3.83%)
Current price
EarningsLatest report: Mar 31, 2026
HIGHER-RISK PROFILECautionConfidence: 62%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$1.39B
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.01Healthy liquidity · 41.44Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 12, 2026, 12:00 AM UTCLast profile update: Aug 13, 2026, 12:09 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$49.34
Change3.83%
Shares Out28.24M
Market Cap$1.39B
Enterprise Value$1.03B
52W Range13.36 - 49.14
Beta0.42
P/E-35.57
P/B3.68
P/FCF-26.95
EV/EBITDA-22.27
EV/FCF-19.89

Investment DNA

How strong this company looks for long-term investors

46
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
88/100
Why this score▼
Manageable debt level · 0.01Healthy liquidity · 41.44Weak profitability

Analyst view

Analyst sentiment and price target

LBRX
Analyst sentiment
Based on 3 analyst votes · 2026-09-05
100/100
Bullish
Bullish
3
Hold
0
Bearish
0
Price Target
2026-08-13
Low
$36.00
Mean
$47.86
Median
$45.00
High
$78.00

Company Overview

IPO: 9/11/2025
Industry: Biotechnology
P/B i: 3.68
Debt / Equity i: 0.01
Operating Margin: 0.00%
Net Margin: 0.00%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.01
Current Ratio: 41.44
Quick Ratio: 41.44
Status: Good
🧾

No insider activity

No recent insider transactions available.